medi weight loss tirzepatide results after 8 months on semaglutide GLP-1 (Semaglutide & Tirzepatide) Weight

The body defends against weight loss through mechanisms that increase hunger, reduce energy expenditure, and enhance nutrient absorption efficiency

Key Takeaways: GLP-1 vs GIP Both are incretin hormones released by your intestines after eating GLP-1 primarily affects appetite, gastric emptying, and insulin secretion GIP influences insulin secretion, glucagon regulation, and fat metabolism Single GLP-1 agonists (semaglutide) produce 14.9% average weight loss Dual GLP-1/GIP agonists (tirzepatide) produce 22.5% average weight loss The dual action appears to create additive rather than merely overlapping effects Both receptor types play important roles in metabolic regulation Understanding the difference helps explain why tirzepatide shows superior results What Are Incretin Hormones

Obesity is a major public health challenge in the UK

Tirzepatide is primarily indicated for the treatment of type 2 diabetes

Semaglutide carries an FDA boxed warning for a potential risk of thyroid C-cell tumors